Apogee Therapeutics Announces Agenda for Virtual R&D Day
Apogee Therapeutics (Nasdaq: APGE) announced the agenda for its upcoming virtual R&D Day scheduled for December 2, 2024. The event will feature presentations from key opinion leaders including Dr. Emma Guttman-Yassky and Dr. David Singh, alongside the company's management team. The agenda includes discussions on APG808 Phase 1 clinical trial interim results, APG777 updates, and strategies for addressing atopic dermatitis, asthma, and COPD treatments. The presentations will focus on the company's approach to inflammatory and immunology conditions, particularly through IL-13 and combination therapies.
Apogee Therapeutics (Nasdaq: APGE) ha annunciato l'agenda per il suo prossimo evento virtuale di Ricerca e Sviluppo (R&D Day) previsto per il 2 dicembre 2024. L'evento presenterà interventi di leader di opinione come la Dr.ssa Emma Guttman-Yassky e il Dr. David Singh, insieme al team di gestione dell'azienda. L'agenda include discussioni sui risultati intermedi della fase 1 dello studio clinico di APG808, aggiornamenti su APG777 e strategie per affrontare il trattamento della dermatite atopica, dell'asma e della BPCO. Le presentazioni si concentreranno sull'approccio dell'azienda alle condizioni infiammatorie e immunologiche, in particolare attraverso terapie con IL-13 e combinazioni terapeutiche.
Apogee Therapeutics (Nasdaq: APGE) anunció la agenda de su próximo Día de I+D virtual programado para el 2 de diciembre de 2024. El evento contará con presentaciones de líderes de opinión clave como la Dra. Emma Guttman-Yassky y el Dr. David Singh, junto con el equipo de gestión de la empresa. La agenda incluye discusiones sobre los resultados intermedios del ensayo clínico de fase 1 de APG808, actualizaciones de APG777 y estrategias para abordar el tratamiento de la dermatitis atópica, el asma y la EPOC. Las presentaciones se centrarán en el enfoque de la empresa hacia las condiciones inflamatorias e inmunológicas, especialmente a través de terapias con IL-13 y terapias combinadas.
Apogee Therapeutics (Nasdaq: APGE)가 2024년 12월 2일 예정된 가상 연구 및 개발(R&D) 데이의 일정을 발표했습니다. 이번 행사에는 주요 의견 리더인 Emma Guttman-Yassky 박사와 David Singh 박사가 참여하며, 회사 경영진도 함께할 예정입니다. 일정에는 APG808 1상 임상 시험 중간 결과, APG777 업데이트, 아토피 피부염, 천식, 만성 폐쇄성 폐질환(COPD) 치료를 위한 전략 논의가 포함됩니다. 발표는 염증 및 면역학적 질환에 대한 회사의 접근 방식, 특히 IL-13 및 병용 요법을 통한 치료 방법에 초점을 맞출 것입니다.
Apogee Therapeutics (Nasdaq: APGE) a annoncé l'agenda de son prochain événement virtuel de recherche et développement (R&D Day), prévu le 2 décembre 2024. L'événement comportera des présentations de leaders d'opinion clés tels que Dr. Emma Guttman-Yassky et Dr. David Singh, ainsi que de l'équipe de direction de l'entreprise. L'agenda inclut des discussions sur les résultats intermédiaires des essais cliniques de la phase 1 d'APG808, des mises à jour sur APG777 et des stratégies pour le traitement de la dermatite atopique, de l'asthme et de la BPCO. Les présentations se concentreront sur l'approche de l'entreprise en matière de conditions inflammatoires et immunologiques, notamment grâce aux thérapies IL-13 et aux thérapies combinées.
Apogee Therapeutics (Nasdaq: APGE) hat die Agenda für seinen bevorstehenden virtuellen Tag der Forschungs- und Entwicklungsarbeit (R&D Day), der für den 2. Dezember 2024 geplant ist, bekannt gegeben. Die Veranstaltung umfasst Präsentationen von Schlüsselmeinungsführern wie Dr. Emma Guttman-Yassky und Dr. David Singh sowie dem Management-Team des Unternehmens. Die Agenda beinhaltet Diskussionen über die Zwischenergebnisse der Phase-1-Studie zu APG808, Updates zu APG777 und Strategien zur Behandlung von atopischer Dermatitis, Asthma und COPD. Die Präsentationen werden sich auf den Ansatz des Unternehmens bei entzündlichen und immunologischen Erkrankungen konzentrieren, insbesondere durch IL-13 und Kombinationstherapien.
- Upcoming presentation of APG808 Phase 1 clinical trial interim results
- Development of multiple drug candidates (APG808, APG777) targeting major I&I markets
- Engagement of prominent KOLs supporting company's therapeutic approach
- None.
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET.
Featured Speakers:
Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new treatment opportunities for patients living with I&I conditions.
- Emma Guttman-Yassky, M.D., Ph.D., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City.
- David Singh, M.D., FERS, FBPhS, Respiratory Physician and Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester in the UK.
R&D Day Agenda:
- Apogee’s vision for building a next-gen biotech
- APG808 Phase 1 clinical trial interim results
- Building a leading franchise in AD
- APG777 PK and PD updates
- Broader cytokine targeting can better address heterogeneity in AD (KOL)
- IL-13 + OX40L combination has the potential to raise the bar in AD
- Breaking through the efficacy ceiling in asthma and COPD
- Alarmins and Type 2 cytokines in obstructive airway disease (KOL)
- IL-13 + TSLP combination targets both central and local drivers of obstructive airway disease
- Commercial opportunity and strategy
- Closing remarks and Q&A
To join the webcast, please visit this link or the News & Events page of the Investors section on the Company’s website https://apogeetherapeutics.com. A replay of the webcast will be archived and available following the event.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Apogee Therapeutics (APGE) hosting its R&D Day?
What clinical trial results will APGE present at the R&D Day?
Which therapeutic areas is APGE targeting with its drug development?
